Skip to content
Kyowa Kirin
-
Kyowa Kirin signs exclusive Poteligeo distribution deal with Knight Therapeutics in Latin America
The deal gives Kyowa Kirin access to Knight’s pan-American commercial infrastructure while allowing Knight to add a targeted oncology therapy to its portfolio.
-
Kyowa Kirin extends Crysvita EU orphan market exclusivity to February 2030
The approval follows a positive recommendation issued in April 2026 by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
-
Kyowa Kirin expands FDA-approved use of Crysvita for adults with XLH
The treatment is approved in the United States for adults and pediatric patients aged six months and older, making it one of the few targeted therapies available for this condition.